Falling sales of OTC and other diagnostics, on one hand, and regaining infant formula market share on the other take a back seat in Abbott’s latest results as the firm debuts its Lingo line of consumer bio-wearables in the UK.
CEO Robert Ford said during Abbott’s earnings briefing on 20 July that the firm plans to file for US approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?